Article about NEU competitors still in the race for Rett treatment.
Rett failure sets up thin pipelinehttps://www.evaluate.com/vantage/articles/news/trial-results/rett-failure-sets-thin-pipeline
Phase III pipeline for Rett treatment includes Trofinetide (Acadia), Anavex 2-73 (Anavex), Epidiolex (GW Pharmaceuticals). Indicated sales for each treatment ($US126m for Trofinetide) shown in article are less than I was expecting.
Article about NEU competitors still in the race for Rett...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |